Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NOTCH3
REST API REST API
Homo sapiens
NOTCH3 is differentially expressed in 269 experiments: 170 organism parts: bone marrow, liver, ... (168 more);, 254 disease states: normal, prostate carcinoma, ... (252 more);, 79 cell types 435 cell lines 29 compound treatments and 74 other conditions.
Synonyms CADASIL, CASIL
Orthologs notch3 (Danio rerio)   Q2L697_CIOIN (Ciona intestinalis)   Notch3 (Rattus norvegicus)   Notch3 (Mus musculus)   NOTCH3 (Bos taurus)   N (Drosophila melanogaster)   notch3 (Xenopus laevis)   NOTCH3 (Canis familiaris)   (Compare orthologs)
InterPro Term Notch_dom, Notch_NOD_dom, Ankyrin_rpt, Ankyrin_rpt-contain_dom, EGF_extracell, EGF, EGF_3, Notch, Notch_NODP_dom, EGF-like, Notch_3, DUF3454_notch, EGF-like_Ca-bd
Gene Ontology Term cytosol, plasma membrane, protein binding, regulation of transcription, DNA-dependent, membrane, extracellular region, cell differentiation, tissue regeneration, Notch receptor processing, multicellular organismal development, nucleus, receptor activity, Notch signaling pathway, regulation of developmental process, integral to membrane, nucleoplasm, negative regulation of cell differentiation, endoplasmic reticulum lumen, calcium ion binding, Golgi lumen, forebrain development, gene expression, glomerular capillary formation, negative regulation of neuron differentiation, neuron fate commitment, positive regulation of smooth muscle cell proliferation
UniProt Accession B8XFT4, Q9UM47
Gene-Disease Assocation CEREBRAL ARTERIOPATHY, AUTOSOMAL DOMINANT, WITH SUBCORTICAL INFARCTS
Search EB-eye ENSG00000074181
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (42 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-62, E-MTAB-37, E-MEXP-440
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC38
2
E-MTAB-37, E-MTAB-62
LNCaP
2
E-GEOD-14990, E-GEOD-14464
429 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-360, E-GEOD-13909, ... (41 experiments)

Factor Value U/D Experiments
plasma cell
2
E-MEXP-2360, E-GEOD-6691
embryonic stem cell derived mesenchymal stem cell
1
E-GEOD-2248
immortalised T lymphocytes
1
E-GEOD-13909
CD8+ T cell
1
E-MTAB-25
BDCA1+ dendritic cell
1
1
E-TABM-34
double positive thymocyte
1
E-GEOD-1460
73 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (62 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-GEOD-96, E-MEXP-2034, E-MTAB-62, E-GEOD-7307
glioblastoma
3
E-GEOD-4290, E-MTAB-62, E-GEOD-6014
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
lymphoma
2
E-MTAB-37, E-MTAB-62
sarcoma
2
E-MTAB-62, E-MTAB-37
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MTAB-62, E-MEXP-66
248 more value(s).


Compound treatment

studied in E-GEOD-5824, E-GEOD-5099, E-GEOD-6462, E-MEXP-1958, E-GEOD-1925, ... (20 experiments)

Factor Value U/D Experiments
none
1
5
E-GEOD-5824, E-MEXP-1958, E-GEOD-1925, E-GEOD-5099, E-GEOD-20719, ... (6 experiments)
untreated
1
E-GEOD-15389
actinomycin D
1
E-GEOD-6400
selenium
1
E-MEXP-1327
CNOT7+CNOT8
1
1
E-MEXP-2218
mannitol
1
E-GEOD-6400
23 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-2191, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-MEXP-2359, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-20847, E-MTAB-108, E-MEXP-563

Genotype
studied in E-GEOD-22056, E-GEOD-2466, E-GEOD-17476, E-GEOD-2292, E-TABM-321, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-6432, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446, ... (8 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-26, ... (28 experiments)

Infection
studied in E-GEOD-2405, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, E-GEOD-2487 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-19330

RNAi
studied in E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-33562, E-GEOD-19246, E-GEOD-19136, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.333 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM